Search

Your search keyword '"Stilgenbauer, Stephan"' showing total 57 results

Search Constraints

Start Over You searched for: Author "Stilgenbauer, Stephan" Remove constraint Author: "Stilgenbauer, Stephan" Database Springer Nature Journals Remove constraint Database: Springer Nature Journals
57 results on '"Stilgenbauer, Stephan"'

Search Results

2. The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network

6. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial

7. Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

8. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

9. Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis

11. Profile of the multicenter cohort of the German Cancer Consortium’s Clinical Communication Platform

12. Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic

13. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome

14. Molecular map of chronic lymphocytic leukemia and its impact on outcome

15. Kapazität der onkologischen Versorgung in deutschen onkologischen Spitzenzentren während der ersten 2 Jahre der COVID-19-Pandemie

16. Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial

17. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial

18. The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia

20. Proteogenomics refines the molecular classification of chronic lymphocytic leukemia

21. Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape

23. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations

24. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials

25. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia

26. Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas

27. Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

31. Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia

34. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial

35. COVID-19 among fit patients with CLL treated with venetoclax-based combinations

36. Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group

37. Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy

39. Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study

41. Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL

43. Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study

44. Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia

46. CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia

49. Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL

Catalog

Books, media, physical & digital resources